Skip to content
10-Q

Quarterly Report

INOZYME PHARMA, INC.

0000950170-24-053981

← back to feed
Filed
May 7, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 2, 2024 61.86M sh
Long Term Debt Q1 2024 · Mar 31, 2024 $45.03M
Long Term Debt Q1 2024 · Dec 31, 2023 $44.77M
Short Term Investments Q1 2024 · Mar 31, 2024 $145.54M
Short Term Investments Q1 2024 · Dec 31, 2023 $154M
Current Liabilities Q1 2024 · Mar 31, 2024 $12.41M
Current Liabilities Q1 2024 · Dec 31, 2023 $14.69M
Total Liabilities Q1 2024 · Mar 31, 2024 $58.11M
Total Liabilities Q1 2024 · Dec 31, 2023 $60.37M
Current Assets Q1 2024 · Mar 31, 2024 $174.32M
Current Assets Q1 2024 · Dec 31, 2023 $196.25M
Total Assets Q1 2024 · Mar 31, 2024 $176.94M
Total Assets Q1 2024 · Dec 31, 2023 $200.85M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $34.59M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $49.02M
Shares Diluted Q1 2024 · Mar 31, 2023 43.72M sh
Capex Q1 2024 · Mar 31, 2023 $175K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$17.77M
Stockholders Equity Q1 2024 · Mar 31, 2023 $103.35M
Stockholders Equity Q1 2024 · Dec 31, 2022 $118.39M
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.40
Eps Basic Q1 2024 · Mar 31, 2023 −$0.40
Sga Expense Q1 2024 · Mar 31, 2023 $6.51M
Rd Expense Q1 2024 · Mar 31, 2023 $11.86M
Net Income Q1 2024 · Mar 31, 2023 −$17.4M
Operating Income Q1 2024 · Mar 31, 2023 −$18.37M